⌘K
t
Tristel plc announced on 10 June 2026 that it issued and allotted 11,000 new ordinary shares of 1 penny each following the exercise of options by employees. Application for admission of these shares to AIM has been made, with admission expected on 15 June 2026 at 8:00 a.m. After admission, the total number of ordinary shares and voting rights will be 47,997,293.
| Date | 10 Jun 2026 |
| Time | 07:00:05 |
| Category | Capital structure |
| ID | 6568H |
10 June 2026
Tristel plc
("Tristel" or the "Company")
Exercise of Share Options and Total Voting Rights
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that it has issued and allotted a total of 11,000 new ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") following the exercise of options by employees of the Company.
Application has been made to the London Stock Exchange for the 11,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 15 June 2026.
Total Voting Rights
After Admission, the total number of Ordinary Shares in issue will be 47,997,293 and the total number of voting rights will therefore be 47,997,293. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information please contact:
|
Tristel plc |
Via Walbrook PR |
|||
|
Matt Sassone, Chief Executive Officer |
||||
|
Anna Wasyl, Chief Financial Officer |
|
|||
|
|
|
|||
|
Walbrook PR Ltd |
Tel: 020 7933 8780 or [email protected] |
|||
|
Paul McManus / Lianne Applegarth / Anna Dunphy |
Mob: 07980 541 893/ 07584 391 303/ 07876 741 001 |
|||
|
|
|
|||
|
Cavendish Capital Markets Ltd |
Tel: 020 7220 0500 |
|||
|
Geoff Nash / Callum Davidson / Joe Smith (Corporate Finance) |
|
|||
|
Sunila de Silva (Corporate Broking) / Louise Talbot (Sales) |
|
|||
About Tristel plc
Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals with products under the Tristel brand, which also encompasses its sporicidal surface disinfection range offered as a sustainable alternative to commonly used pre‑wetted plastic wipe.
Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets delivering double-digit revenue growth annually, an adjusted EBITDA margin of at least 25% and a continuing progressive year-on-year growth in dividends, underpinned by robust cash generation.
The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).
For more information about Tristel's product range please visit: https://tristel.com